EUVIMEDEUVIMED entdecken
Crossref

Longer-term outcomes of intravitreal therapy for neovascular age-related macular degeneration at a peripheral centre (Palmerston North eye clinic)

Brandon Nunns, Aqeeda Singh, John Ah-Chan

New Zealand Medical Journal · 2026

DOI: 10.26635/6965.7545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New Zealand Medical Journal, 2026. Verfasst von Brandon Nunns und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Registrar, Wellington Hospital, Wellington, New Zealand. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Macular Degeneration, Ranibizumab, Bevacizumab.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

aim: The aim of this study was to evaluate long-term real-world outcomes of anti–vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD) at a regional New Zealand centre, with a primary focus on treatment duration and reasons for cessation. methods: A retrospective cohort study was conducted at Palmerston North eye clinic, including all newly diagnosed eyes with nAMD initiating anti-VEGF therapy between November 2017 and August 2023. Demographic data, visual acuity, treatment duration and documented reasons for cessation were extracted from a prospectively maintained database and validated against electronic health records. results: Among 527 eyes from 446 patients, 39.8% ceased treatment. The most common reasons were end-stage disease (44.8%), patient death (21.9%), logistical factors (17.6%) and injection intolerance (8.1%). Mean treatment duration was 421 days. Visual outcomes were favourable overall with 20.2% of eyes improving and 59.5% remaining stable. Better baseline visual acuity strongly predicted better final vision. conclusions: High early cessation due to end-stage disease suggests possible late presentation, underscoring the need for earlier detection and referral. Addressing logistical barriers and supporting adherence will be increasingly important as demand for anti-VEGF therapy grows with an ageing population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsMacular DegenerationRanibizumabBevacizumabHumansFemaleRetrospective StudiesMaleIntravitreal InjectionsNew ZealandAgedVisual AcuityVascular Endothelial Growth Factor AAged, 80 and overTreatment Outcome

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumabBevacizumab

Autor:innen und Institutionen

  • Ophthalmology Registrar, Wellington Hospital, Wellington, New Zealand.
  • Ophthalmology Training Registrar, Dunedin Hospital, Dunedin, New Zealand.
  • Consultant Ophthalmologist, Palmerston North Hospital, Palmerston North, New Zealand.

Zitieren

APA

Nunns, B., Singh, A., & Ah-Chan, J. (2026). Longer-term outcomes of intravitreal therapy for neovascular age-related macular degeneration at a peripheral centre (Palmerston North eye clinic). New Zealand Medical Journal. https://doi.org/10.26635/6965.7545

Vancouver

Nunns B, Singh A, Ah-Chan J. Longer-term outcomes of intravitreal therapy for neovascular age-related macular degeneration at a peripheral centre (Palmerston North eye clinic). New Zealand Medical Journal. 2026. doi:10.26635/6965.7545

BibTeX
@article{Nunns2026,
  author = {Nunns, Brandon and Singh, Aqeeda and Ah-Chan, John},
  title = {Longer-term outcomes of intravitreal therapy for neovascular age-related macular degeneration at a peripheral centre (Palmerston North eye clinic)},
  journal = {New Zealand Medical Journal},
  year = {2026},
  doi = {10.26635/6965.7545}
}
Kostenlos starten →